The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats

<p>Abstract</p> <p>Background</p> <p>Activation of peroxisome proliferator-activated receptor (PPAR)gamma is associated with bone loss and increased fracture risk, while PPARalpha activation seems to have positive skeletal effects. To further explore these effects we ha...

Full description

Bibliographic Details
Main Authors: Eriksen Erik F, Waarsing Jan H, Fossmark Reidar, Gustafsson Björn I, Westbroek Irene, Stunes Astrid K, Petzold Christiane, Reseland Janne E, Syversen Unni
Format: Article
Language:English
Published: BMC 2011-05-01
Series:BMC Endocrine Disorders
Online Access:http://www.biomedcentral.com/1472-6823/11/11